Ali Mortazavi, CEO of e-Therapeutics PLC (AIM:ETX, OTCQX:ETXPF), addressed the challenges of traditional drug discovery, emphasising its high risk, extensive timeline, and considerable cost at the Proactive One2One Investor Forum.
Underlining the inefficiencies of this model, Mortazavi posed the question: Can we compute the future of medicine and is drug discovery essentially a data science problem? The answer, he believes, has shifted from a "maybe" to a definitive "yes" in light of advances in AI language models.
Mortazavi highlighted the company's innovative drug platform that targets the liver, a crucial organ with a role extending beyond just liver diseases. He described the liver as the "Amazon hub" of the human body, processing information and impacting various diseases across organs. The company boasts a vast data centre, drawing from a plethora of sources, providing insight into gene-disease pairs.
A turning point for e-Therapeutics was the integration of generative AI systems in March 2023. These AI systems, which can understand, reason, and make inferences, have revolutionised their approach. They have specialised these AI agents to become experts in liver genes and diseases, pushing closer to their goal of computing the future of medicine.
